NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 185)
Posted On: 12/20/2023 3:54:38 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held on Dec. 19, 2023, all matters considered by shareholders were approved; agenda items were sent to shareholders in a notice of meeting and management information communication that was released on Oct. 27, 2023. In addition, shareholders approved the election of five directors, including Eric A. Adams, Janet Grove, Andrew Hull, Nicole Lemerond and Bryan Baldasare; directors will hold their office until the next annual meeting or until successors are elected and appointed. The company noted that 1,292,647 common shares of the company were represented at the meeting, either in person or by proxy, which represents almost 39% of the company’s 3,328,191 issued and outstanding shares.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held on Dec. 19, 2023, all matters considered by shareholders were approved; agenda items were sent to shareholders in a notice of meeting and management information communication that was released on Oct. 27, 2023. In addition, shareholders approved the election of five directors, including Eric A. Adams, Janet Grove, Andrew Hull, Nicole Lemerond and Bryan Baldasare; directors will hold their office until the next annual meeting or until successors are elected and appointed. The company noted that 1,292,647 common shares of the company were represented at the meeting, either in person or by proxy, which represents almost 39% of the company’s 3,328,191 issued and outstanding shares.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)